Claims for Patent: 5,844,099
✉ Email this page to a colleague
Summary for Patent: 5,844,099
Title: | Cytokine antagonists |
Abstract: | Heteromeric proteins comprising a soluble .alpha. specificity determining cytokine receptor component and the extracellular domain of a .beta. receptor component function as cytokine antagonists. |
Inventor(s): | Stahl; Neil (Carmel, NY), Economides; Aris (Dobbs Ferry, NY), Yancopoulos; George D. (Yorktown Heights, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 08/563,105 |
Patent Claims: | 1. A purified antagonist of a cytokine comprising:
a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the cytokine's receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of a signal transducing component of the cytokine's receptor; wherein the cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-15, granulocyte macrophage colony stimulating factor, gamma-interferon, and Transforming Growth Factor-Beta, and the antagonist is capable of binding the cytokine to form a nonfunctional complex. 2. The purified antagonist according to claim 1, which further comprises an immunoglobulin derived domain capable of forming a complex between said extracellular domain of said specificity determining component and said extracellular domain of said signal transducing component. 3. The purified antagonist according to claim 2, in which said immunoglobulin domain is the Fc domain of IgG. 4. The purified antagonist according to claim 2, in which said immunoglobulin domain is a heavy chain of IgG. 5. The purified antagonist according to claim 4, in which said heavy chain is C-gamma1 or C-gamma4. 6. The purified antagonist according to claim 2, in which said immunoglobulin domain is a light chain of IgG. 7. The purified antagonist according to claim 6, in which said light chain is the kappa chain of IgG. 8. The purified antagonist according to claim 6, in which said light chain is the lambda chain of IgG. 9. A purified antagonist of interleukin-1 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-1 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-1 receptor; wherein the antagonist is capable of binding interleukin-1 to form a nonfunctional complex. 10. A purified antagonist of interleukin-2 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-2 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-2 receptor; wherein the antagonist is capable of binding interleukin-2 to form a nonfunctional complex. 11. A purified antagonist of interleukin-3 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-3 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-3 receptor; wherein the antagonist is capable of binding interleukin-3 to form a nonfunctional complex. 12. A purified antagonist of interleukin-4 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-4 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-4 receptor; wherein the antagonist is capable of binding interleukin-4 to form a nonfunctional complex. 13. A purified antagonist of interleukin-5 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-5 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-5 receptor; wherein the antagonist is capable of binding interleukin-5 to form a nonfunctional complex. 14. A purified antagonist of interleukin-15 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-15 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-15 receptor; wherein the antagonist is capable of binding interleukin-15 to form a nonfunctional complex. 15. A purified antagonist of granulocyte macrophage colony stimulating factor comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the granulocyte macrophage colony stimulating factor receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the granulocyte macrophage colony stimulating factor receptor; wherein the antagonist is capable of binding granulocyte macrophage colony stimulating factor to form a nonfunctional complex. 16. A purified antagonist of gamma-interferon comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the gamma-interferon receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the gamma-interferon receptor; wherein the antagonist is capable of binding gamma-interferon to form a nonfunctional complex. 17. A purified antagonist of Transforming Growth Factor-Beta comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the Transforming Growth Factor-Beta receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the Transforming Growth Factor-Beta receptor; wherein the antagonist is capable of binding Transforming Growth Factor-Beta to form a nonfunctional complex. |
Details for Patent 5,844,099
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | February 27, 2008 | ⤷ Sign Up | 2013-10-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,844,099
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 948242 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 9511303 | ⤷ Sign Up |
United States of America | 5470952 | ⤷ Sign Up |
Portugal | 726954 | ⤷ Sign Up |
Japan | H09504030 | ⤷ Sign Up |
Japan | 3961562 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.